Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.43 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477510 | 0.89 | KDM4E (0.47) | POLBMAPTTP53ALDH1A1GAA | |
| SCHEMBL4491139 | 0.84 | CA1 (0.52) | ALDH1A1HPGD | |
| SCHEMBL4487073 | 0.83 | KDM4E (0.53) | POLBMAPTTP53ALDH1A1GAA | |
| SCHEMBL4487160 | 0.81 | HPGDS (0.47) | POLBMAPTALDH1A1HPGD | |
| SCHEMBL4489260 | 0.80 | HPGDS (0.55) | LMNAMAPTTP53ALDH1A1HPGD | |
| SCHEMBL4490500 | 0.80 | CTNNB1 (0.51) | POLBLMNAMAPTMEN1KMT2A | |
| SCHEMBL4482149 | 0.80 | KDM4E (0.47) | MAPTMEN1KMT2A | |
| SCHEMBL4489494 | 0.79 | HIF1A (0.60) | POLBLMNAMAPTTP53ALDH1A1 | |
| SCHEMBL4484614 | 0.79 | KDM4E (0.46) | LMNAMAPTTP53ALDH1A1MEN1 | |
| SCHEMBL4492223 | 0.78 | CCR9 (0.47) | LMNAMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482455-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-27 | — | — | US | claimed |
| EP-1556379-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-06-13 | — | — | EP | claimed |
| US-20060106058-A1 | Chemical compounds | BURGESS JOELLE L | 2006-05-18 | — | — | US | claimed |
| EP-1556379-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004034985-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | claimed |
| US-7482455-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1556379-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20060106058-A1 | Chemical compounds | BURGESS JOELLE L | 2006-05-18 | — | — | US | disclosed |
| EP-1556379-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004034985-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106058-A1 | Chemical compounds | YARS1, DAPK3, NEK3 | POLB 2602/4885LMNA 2030/4885GFER 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.